SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid buzz over its strategic agreement with Meta Platforms to power AI data centers and a U.S. Department of Energy deal for a radioisotope pilot facility. The community is intensely discussing whether the company's long-term potential in advanced nuclear energy, bolstered by government initiatives and AI's immense power needs, outweighs its current lack of commercial revenue. Anticipation builds around an upcoming congressional hearing on nuclear energy dominance, which investors believe could further accelerate its market position.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is generating significant buzz as its pivotal PDUFA date for Anaphylm rapidly approaches, with many anticipating a potential game-changing approval for the device-free epinephrine film. Community discussion highlights Anaphylm's unique convenience and the FDA waiving an Advisory Committee meeting as strong positive signals, while a substantial short interest fuels speculation of an impending squeeze. Conversely, some investors remain cautious, weighing past regulatory challenges against the promise of a novel, needle-free allergy treatment.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending amid extreme volatility and a significant price decline, with many in the community citing aggressive market 'manipulation' or 'fkkery'. Despite some expectations for a 'polar payday' driven by potential colder weather, the leveraged ETF faces relentless selling pressure, prompting discussions of capitulation, impending reverse splits, and its inherent decay as it tracks natural gas futures.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending due to recent policy moves aimed at driving down mortgage rates, which has ignited strong community optimism for a revitalized housing market. Investors are actively discussing the potential for increased transaction volume and a significant price appreciation, with many anticipating a move towards double-digit levels for the company's stock.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is actively trending as it solidifies strategic nuclear energy partnerships with companies like Vistra and Oklo, a move critically observed by the community as indispensable for powering its ambitious AI data center expansion. This development highlights the escalating energy demands of the AI race, prompting discussions among investors about Meta's long-term vision and its ability to execute. Additionally, China's review of Meta's Manus AI acquisition is generating buzz, adding a layer of geopolitical interest to the company's recent activities.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending amidst heightened discussions regarding the critical role of Small Modular Reactors in meeting the escalating energy demands from AI data centers and broader market needs. The community is actively debating the company's long-term potential as the sole NRC-approved SMR provider, with bulls pointing to anticipated government support and contracts, while others express caution regarding its pre-revenue state and historical volatility. This positions NuScale Power within a broader conversation about the future of energy infrastructure for next-generation technology.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) is trending following overwhelmingly positive feedback from its FDA Type B meeting, confirming a clear path for its sonelokimab (SLK) Biologics License Application (BLA) in hidradenitis suppurativa without additional clinical trials. This significant de-risking event has ignited strong optimism among investors, who anticipate substantial analyst upgrades and a renewed focus on potential acquisition by larger pharmaceutical companies, particularly given SLK's strong position in the immunology market. Community discussions highlight the belief that the stock is fundamentally undervalued, expecting a significant re-rating as regulatory clarity and strategic appeal of the asset drive conversation.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending following the completed Renergen acquisition, which integrates helium and LNG production, and an 'Overweight' analyst rating from Cantor Fitzgerald. The community views these developments as key steps differentiating ASPI in the high-growth nuclear and materials sector, particularly for its potential in HALEU for advanced reactors and silicon-28 for AI computing. Discussions highlight the company's strategic positioning within the broader 'atomic renaissance' amidst anticipation of future revenue streams.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is a trending topic amidst its active participation at CES 2026, where it is showcasing advancements in agentic voice and visual AI for vehicles and smart devices, alongside new partnerships with TomTom and Richtech Robotics. The community is buzzing with both optimism for significant growth and a potential short squeeze, given its high short interest, while some express frustration over perceived price suppression despite positive developments. This highlights a broader market focus on the real-world deployment of conversational and agentic AI across various industries.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, Sunset, and Asset Closure. The Retail segment sells electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Sunset segment includes generation plants with announced retirement plans. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp (VST) is trending as it aggressively expands its power generation capacity, notably with a $4 billion acquisition of Cogentrix Energy's natural gas fleet, directly addressing the surging electricity demand from AI data centers. This strategic move, complementing earlier nuclear power contracts, positions Vistra as a pivotal supplier for hyperscalers, with the community actively debating its role in solving the critical 'AI energy bottleneck' amid recent market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Microbot Medical (NASDAQ:MBOT) Posts Earnings Results, Misses Expectations By $0.01 EPS

Microbot Medical (NASDAQ:MBOT - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the...

Down 28.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Microbot Medical (MBOT)

Microbot Medical (MBOT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval

STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.

All You Need to Know About Microbot Medical (MBOT) Rating Upgrade to Buy

Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System

MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.

Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market

MBOT's new U.S. patent boosts the LIBERTY system's flexibility, expanding its U.S. market reach to over six million annual procedures.

Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?

Beat the Market the Zacks Way: Ryanair, Monster Beverage, Ulta Beauty in Focus

One of the greatest challenges retail investors face is figuring out which stock is undervalued and finding the right entry point to buy that stock. However, history shows that these are the points where investors falter most often.Stocktwits recently conducted a poll asking users on the platform which stock in the robotics sector has the most upside in 2025. Of the three names—Richtech Robotics Inc. (RR), Serve Robotics Inc. (SERV), and Microbot Medical Inc. (MBOT)—retail investors chose to side with RR, which has witnessed the most downside over the last year.<figure class="image"><img style="aspect-ratio:1320/766;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/RR_poll_and_results_abc2021e3e.png" alt="RR poll and results.png" width="1320" height="766"></figure>Richtech Robotics lost nearly 59% of its market capitalization during this period, compared to SERV's almost 28% loss and MBOT's 43% gain.Even from a year-to-date perspective, RR stock has gained just about 14%, SERV has risen over 27%, and MBOT has increased over 80%. This leaves more room for RR to pare its losses after last year’s disappointing performance.Interestingly, it appears retail investors are betting on the stock that seems to be undervalued due to its price movement. The question is whether a significant decline in stock price indicates an equally lucrative potential for a reversion to the mean or a persisting weakness in the fundamentals.Another notable metric appears to be the short interest on these stocks. According to KoyFin, RR has the lowest short interest among the three names of about 3.1% while MBOT has a short interest of about 3.4% and SERV has a short interest of about 5.7%. Although the numbers do not seem significant, the needle still points toward RR as the best choice.Investor perception, too, is a crucial deciding factor. While MBOT stock appears to be the least undervalued of the three stocks, SERV shares have drawn some negative reactions recently. The company announced $80 million worth of direct offering, drawing negative reactions from investors.This development also favors RR as the stock with the most upside this year.However, markets never cease to surprise, and with 2025 just two weeks old, investors will have plenty of time to assess how the evolving macro picture affected these companies' fundamentals.It will also be interesting to analyze whether the much-talked-about mean reversion worked for RR stock.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gbtg-stock-falls-on-dojs-lawsuit/chGWtrMRZC">Global Business Travel Group Stock Falls On DOJ’s Lawsuit To Block Acquisition Of CWT Holdings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market data with uptrend vector | Illustration Source: Getty Images

Stocktwits Poll: Retail Investors Bet RR Stock Will Have Most Upside In 2025 Among Robotics Players

Richtech Robotics lost nearly 59% of its market capitalization in the period, compared to a nearly 28% loss posted by SERV and a 43% gain registered by MBOT during the period.

Equity

Richtech Robotics lost nearly 59% of its market capitalization in the period, compared to SERV's nearly 28% loss and MBOT's 43% gain.

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Microbot Medical Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$2.19
Prev Close	$2.11
Open	$2.09
Dividend Yield	0.00%
50-Day Moving Average	$2.15
Beta	1.55
Avg. Volume	2.07M
PE Ratio	-4.83

52-Week High	$4.67
52-Week Low	$1.25
Market Capitalization	$141.7M
EPS (Annual)	-$0.7314
Price to Book	1.84
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MBOT
Microbot Medical Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MBOT News

MBOTMicrobot Medical Inc